Timothy Best
Gilead Sciences (Australia)(AU)Kite (United States)(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, SARS-CoV-2 and COVID-19 Research, Biosimilars and Bioanalytical Methods, Immunotherapy and Immune Responses
Most-Cited Works
- → Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma(2011)166 cited
- → A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus(2014)88 cited
- → A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32(2011)71 cited
- → Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2(2021)56 cited
- → Humoral Response Dynamics Following Infection with SARS-CoV-2(2020)55 cited
- → A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology(2016)54 cited
- → Evaluating metagenomics and targeted approaches for diagnosis and surveillance of viruses(2024)40 cited
- → Evolution of viral variants in remdesivir‐treated and untreated SARS‐CoV‐2‐infected pediatrics patients(2021)19 cited
- Two forms of encephalitis in opportunistic toxoplasmosis.(1979)
- → Using Whole Genome Sequences to Investigate Adenovirus Outbreaks in a Hematopoietic Stem Cell Transplant Unit(2021)17 cited